Profectus BioSciences Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
15
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$11.3M
Profectus BioSciences General Information
Description
Developer of preventive, therapeutic, and oncolytic vaccines designed to treat and prevent viral diseases. The company's vaccines are used for infectious diseases and cancer immunotherapy, enabling people to get prevention from diseases like HCV, HPV, HSV, HIV, and malaria.
Contact Information
Website
www.profectusbiosciences.comCorporate Office
- 6411 Beckley Street
- Suite 201
- Baltimore, MD 21224
- United States
Corporate Office
- 6411 Beckley Street
- Suite 201
- Baltimore, MD 21224
- United States
Profectus BioSciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 23. Merger/Acquisition | 11-Feb-2020 | $11.3M | Completed | Generating Revenue | ||
| 22. Grant | 14-Jan-2019 | Completed | Generating Revenue | |||
| 21. Grant | 24-Aug-2018 | Completed | Generating Revenue | |||
| 20. Grant | 06-Jun-2017 | Completed | Generating Revenue | |||
| 19. Later Stage VC | 12-Dec-2016 | Completed | Generating Revenue | |||
| 18. Grant | 09-Dec-2015 | Completed | Generating Revenue | |||
| 17. Grant | 22-Oct-2014 | Completed | Generating Revenue | |||
| 16. Later Stage VC (Series C) | 04-Aug-2014 | Completed | Generating Revenue | |||
| 15. Grant | 01-Mar-2014 | $5.4M | $30.7M | Completed | Generating Revenue | |
| 14. Grant | 09-May-2012 | $5.6M | $30.7M | Completed | Generating Revenue |
Profectus BioSciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 12,500,000 | $0.000100 | $0.1 | $1.2 | $1.2 | 1x | $1.2 | 21.08% |
Profectus BioSciences Comparisons
Industry
Financing
Details
Profectus BioSciences Competitors (19)
One of Profectus BioSciences’s 19 competitors is Cyanvac, a Venture Capital-Backed company based in Athens, GA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cyanvac | Venture Capital-Backed | Athens, GA | ||||
| Theravectys | Venture Capital-Backed | Paris, France | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Brainstorm Cell Therapeutics | Corporation | New York, NY | ||||
| Sanofi Pasteur | Corporation | Paris, France |
Profectus BioSciences Patents
Profectus BioSciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2015225553-A1 | Recombinant isfahan viral vectors | Active | 01-Mar-2014 | ||
| AU-2015225553-B2 | Recombinant isfahan viral vectors | Inactive | 01-Mar-2014 | ||
| CA-2941261-A1 | Recombinant isfahan viral vectors | Pending | 01-Mar-2014 | ||
| EP-3113795-A2 | Recombinant isfahan viral vectors | Active | 01-Mar-2014 | ||
| EP-3113795-A4 | Recombinant isfahan viral vectors | Active | 01-Mar-2014 | C12N7/00 |
Profectus BioSciences Signals
Profectus BioSciences Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aberdeen Proving Ground | Government | |||
| Cross Atlantic Capital Partners | Venture Capital | Minority | ||
| Department of the Army | Government | |||
| Division of AIDS | Government | |||
| Maryland Industrial Partnerships | University | Minority |
Profectus BioSciences Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| rel-MD | Baltimore, MD | 2011 |
Profectus BioSciences FAQs
-
When was Profectus BioSciences founded?
Profectus BioSciences was founded in 2002.
-
Where is Profectus BioSciences headquartered?
Profectus BioSciences is headquartered in Baltimore, MD.
-
What is the size of Profectus BioSciences?
Profectus BioSciences has 15 total employees.
-
What industry is Profectus BioSciences in?
Profectus BioSciences’s primary industry is Discovery Tools (Healthcare).
-
Is Profectus BioSciences a private or public company?
Profectus BioSciences is a Private company.
-
What is the current valuation of Profectus BioSciences?
The current valuation of Profectus BioSciences is .
-
What is Profectus BioSciences’s current revenue?
The current revenue for Profectus BioSciences is .
-
How much funding has Profectus BioSciences raised over time?
Profectus BioSciences has raised $38.5M.
-
Who are Profectus BioSciences’s investors?
Aberdeen Proving Ground, Cross Atlantic Capital Partners, Department of the Army, Division of AIDS, and Maryland Industrial Partnerships are 5 of 9 investors who have invested in Profectus BioSciences.
-
Who are Profectus BioSciences’s competitors?
Cyanvac, Theravectys, Inovio Pharmaceuticals, Brainstorm Cell Therapeutics, and Sanofi Pasteur are some of the 19 competitors of Profectus BioSciences.
-
When was Profectus BioSciences acquired?
Profectus BioSciences was acquired on 11-Feb-2020.
-
Who acquired Profectus BioSciences?
Profectus BioSciences was acquired by Aurobindo Pharma USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process